Viyash acquired controlling stake in Symed Labs Limited – a leading manufacturer of APIs in India through secondary purchase from certain existing shareholders of Symed Labs, at an undisclosed valuation.
Viyash also acquired controlling stake in Appco Pharma LLC – a formulations player focused on the US market for an undisclosed amount.
Saraf and Partners acted for and advised CA Hull Investments (an affiliated entity of global investment firm The Carlyle Group) and Viyash Life Sciences Private Limited in undertaking certain acquisitions in pharmaceutical sector in India and US as part of its integrated generic pharmaceutical platform in India.
The team for the Symed transaction was led by Partners Vaibhav Kakkar, Sahil Arora and Snigdhaneel Satpathy along with Senior Associate Debarpan Ghosh and Associates Keshav Pareek and Paayas Pandit.
Partners Sachit Mathur and Astha Singh Trehan also provided assistance in relation to the Real Estate related aspects involved in the deal.
The core transaction team advising Carlyle and Viyash Life Sciences on the Appco Pharma transaction from an Indian regulatory standpoint included Partners Vaibhav Kakkar and Sahil Arora and Senior Associate Debarpan Ghosh.
Ropes and Gray advised Carlyle and Viyash Life Sciences from a US law standpoint.